Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2013 2
2014 2
2017 1
2018 1
2021 3
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG. van den Bent MJ, et al. Among authors: gijtenbeek a. Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016/S1470-2045(21)00090-5. Epub 2021 May 14. Lancet Oncol. 2021. PMID: 34000245 Free PMC article. Clinical Trial.
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.
van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM. van den Bent MJ, et al. Among authors: gijtenbeek a. Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Lancet. 2017. PMID: 28801186 Free PMC article.
Glioma patient-reported outcomes: patients and clinicians.
Peeters M, Ottenheijm G, Bienfait P, Eekers D, Gijtenbeek A, Hanse M, Koekkoek J, van Leeuwen L, Tijssen C, Dirven L, Taphoorn M. Peeters M, et al. Among authors: gijtenbeek a. BMJ Support Palliat Care. 2023 Oct;13(e1):e205-e212. doi: 10.1136/bmjspcare-2020-002699. Epub 2021 Mar 2. BMJ Support Palliat Care. 2023. PMID: 33653735
Head-To-Head Comparison of PET and Perfusion Weighted MRI Techniques to Distinguish Treatment Related Abnormalities from Tumor Progression in Glioma.
Henssen D, Leijten L, Meijer FJA, van der Kolk A, Arens AIJ, Ter Laan M, Smeenk RJ, Gijtenbeek A, van de Giessen EM, Tolboom N, Oprea-Lager DE, Smits M, Nagarajah J. Henssen D, et al. Among authors: gijtenbeek a. Cancers (Basel). 2023 May 5;15(9):2631. doi: 10.3390/cancers15092631. Cancers (Basel). 2023. PMID: 37174097 Free PMC article. Review.
A bilateral foot drop due to neuroschistosomiasis.
Wilbers J, Idema A, Gijtenbeek A. Wilbers J, et al. Among authors: gijtenbeek a. J Neurol. 2010 May;257(5):853-5. doi: 10.1007/s00415-010-5464-0. Epub 2010 Feb 3. J Neurol. 2010. PMID: 20127348
Apparent Diffusion Coefficient Metrics to Differentiate between Treatment-Related Abnormalities and Tumor Progression in Post-Treatment Glioblastoma Patients: A Retrospective Study.
van den Elshout R, Herings SDA, Mannil M, Gijtenbeek AMM, Ter Laan M, Smeenk RJ, Meijer FJA, Scheenen TWJ, Henssen DJHA. van den Elshout R, et al. Among authors: gijtenbeek amm. Cancers (Basel). 2023 Oct 14;15(20):4990. doi: 10.3390/cancers15204990. Cancers (Basel). 2023. PMID: 37894355 Free PMC article.
Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations.
Tesileanu CMS, Vallentgoed WR, Sanson M, Taal W, Clement PM, Wick W, Brandes AA, Baurain JF, Chinot OL, Wheeler H, Gill S, Griffin M, Rogers L, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, de Vos F, Mulholland PJ, Taphoorn MJB, de Heer I, Hoogstrate Y, de Wit M, Boggiani L, Venneker S, Oosting J, Bovée JVMG, Erridge S, Vogelbaum MA, Nowak AK, Mason WP, Kros JM, Wesseling P, Aldape K, Jenkins RB, Dubbink HJ, Baumert B, Golfinopoulos V, Gorlia T, van den Bent M, French PJ. Tesileanu CMS, et al. Among authors: gijtenbeek a. Acta Neuropathol. 2021 Jun;141(6):945-957. doi: 10.1007/s00401-021-02291-6. Epub 2021 Mar 19. Acta Neuropathol. 2021. PMID: 33740099 Free PMC article.
Rare central nervous system tumors in adults: a population-based study of ependymomas, pilocytic astrocytomas, medulloblastomas, and intracranial germ cell tumors.
Ho VKY, Gijtenbeek AJMM, Wagemakers M, Taal W, van Linde ME, Swaak-Kragten AT, Kurt E, van der Weide HL, Wesseling P, de Vos FY, Bromberg JEC. Ho VKY, et al. Among authors: gijtenbeek ajmm. Neurooncol Adv. 2022 Apr 22;4(1):vdac062. doi: 10.1093/noajnl/vdac062. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35664556 Free PMC article.
Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas.
van Thuijl HF, Scheinin I, Sie D, Alentorn A, van Essen HF, Cordes M, Fleischeuer R, Gijtenbeek AM, Beute G, van den Brink WA, Meijer GA, Havenith M, Idbaih A, Hoang-Xuan K, Mokhtari K, Verhaak RG, van der Valk P, van de Wiel MA, Heimans JJ, Aronica E, Reijneveld JC, Wesseling P, Ylstra B. van Thuijl HF, et al. Among authors: gijtenbeek am. Genome Biol. 2014 Sep 23;15(9):471. doi: 10.1186/s13059-014-0471-6. Genome Biol. 2014. PMID: 25245118 Free PMC article.
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
Bady P, Kurscheid S, Delorenzi M, Gorlia T, van den Bent MJ, Hoang-Xuan K, Vauléon É, Gijtenbeek A, Enting R, Thiessen B, Chinot O, Dhermain F, Brandes AA, Reijneveld JC, Marosi C, Taphoorn MJB, Wick W, von Deimling A, French P, Stupp R, Baumert BG, Hegi ME. Bady P, et al. Among authors: gijtenbeek a. Acta Neuropathol. 2018 Apr;135(4):601-615. doi: 10.1007/s00401-018-1810-6. Epub 2018 Jan 24. Acta Neuropathol. 2018. PMID: 29368212 Free PMC article. Clinical Trial.
14 results